Guiding Icarus: Merging Bioethics with CorporateInterests
Rights Contact Login For More Details
More About This Title Guiding Icarus: Merging Bioethics with CorporateInterests
English
"There is a palpable need for business to explore the issues Dhanda raises. Guiding Icarus offers a flight plan."
-from the Foreword by Philip R. Reilly
Guiding ICARUS
Merging Bioethics with Corporate Interests
Rahul K. Dhanda
While bioethicists may enjoy the most thorough appreciation of both the promise and perils of new biotechnologies, international corporations are in fact the entities generating these technologies and determining their application. An industry insider versed in the language of bioethics, Rahul Dhanda offers in Guiding Icarus: Merging Bioethics with Corporate Interests a Rosetta stone to these two camps, explaining why each needs the other, why their disparate concerns often cohere, and why an ethical business is likely a successful one.
The author develops a dialogue between bioethics and corporate interests by examining case studies of several hot-button issues, including:
* Genetically modified foods
* DNA data banking
* Personalized medicine
* Stem cell research
In each instance he provides a treatment of the particular science under consideration, a list of the benefits of the technology, a description of the ethical issues involved, an account of past industry response, and recommendations for future action. Given the expansive nature of biotechnology, ramifications in the pharmaceutical and agricultural industries are covered in depth as well. The book also features a Foreword by world-renowned bioethicist and biotechnology CEO Philip R. Reilly as well as a step-by-step discussion of the components of business and bioethical issues.
Written for a general audience, Guiding Icarus will be particularly useful to biotechnologists, regulatory affairs managers, and corporate officers of biotechnology firms, as well as bioethicists in the academic community. Dhanda's peerless text provides a unique tool for understanding and addressing the ethical dilemmas confronting society in the 21st century.
-from the Foreword by Philip R. Reilly
Guiding ICARUS
Merging Bioethics with Corporate Interests
Rahul K. Dhanda
While bioethicists may enjoy the most thorough appreciation of both the promise and perils of new biotechnologies, international corporations are in fact the entities generating these technologies and determining their application. An industry insider versed in the language of bioethics, Rahul Dhanda offers in Guiding Icarus: Merging Bioethics with Corporate Interests a Rosetta stone to these two camps, explaining why each needs the other, why their disparate concerns often cohere, and why an ethical business is likely a successful one.
The author develops a dialogue between bioethics and corporate interests by examining case studies of several hot-button issues, including:
* Genetically modified foods
* DNA data banking
* Personalized medicine
* Stem cell research
In each instance he provides a treatment of the particular science under consideration, a list of the benefits of the technology, a description of the ethical issues involved, an account of past industry response, and recommendations for future action. Given the expansive nature of biotechnology, ramifications in the pharmaceutical and agricultural industries are covered in depth as well. The book also features a Foreword by world-renowned bioethicist and biotechnology CEO Philip R. Reilly as well as a step-by-step discussion of the components of business and bioethical issues.
Written for a general audience, Guiding Icarus will be particularly useful to biotechnologists, regulatory affairs managers, and corporate officers of biotechnology firms, as well as bioethicists in the academic community. Dhanda's peerless text provides a unique tool for understanding and addressing the ethical dilemmas confronting society in the 21st century.
English
PHIL LEMPERT has gained wide acclaim for his marketing savvy and broad experience in the food and marketing worlds. A distinguished speaker, he has addressed more than 600,000 people in the past decade alone. Known as the Supermarket Guru, he is widely respected for his ability to predict and analyze trends. He is the food editor and correspondent for NBC News's Today show, host of the nationally syndicated radio show "Shopping Smart," and a correspondent for BBC Radio 5 Live and Public Radio’s KCRW-FM. Lempert has been a columnist for the Chicago Tribune and the Los Angeles Times and is currently the editor of The Lempert Report and Supermarketguru.com, one of the leading Internet resources for food, health, and trend information.
English
Foreword.
Preface.
Acknowledgments.
Introduction.
Genetically Modified Foods.
DNA Data Banking.
Personalized Medicine.
Stem Cells.
Conclusion.
Glossary.
Suggested Reading.
Index.
Preface.
Acknowledgments.
Introduction.
Genetically Modified Foods.
DNA Data Banking.
Personalized Medicine.
Stem Cells.
Conclusion.
Glossary.
Suggested Reading.
Index.
English
"...particularly useful to corporate biotech managers due to Dhanda's explanation of the issues and suggestions on how to engage the public...inherent value in this discourse is how Dhanda explains how an ethical biotech business is likely to be a successful one." (Genomics & Proteomics, May 2002)
"useful to biotechnologists, regulatory affairs managers, and corporate officers of biotech firms, as well as bioethicists..." (Genetic Engineering News, July 2002)
"...if you read The Economist you'll doubtless find this of interest..." (Focus, August 2002)
"...offers an insider's view on why a bridge is needed to merge bioethics with corporate needs...written for the general audience...is especially useful to biotechnologists, regulatory affairs managers, and corporate officers of biotech firms, as well as bioethicists..." (Genetic Engineering News, Vol. 22, No. 13, July 2002)
"...lays out a blueprint for executives...focusing on four subjects..." (HBS (Harvard Business School) Working Knowledge, July 2002)
"This book should stimulate much useful discussion in the biotechnology industry...the author should be congratulated." (Nature Biotechnology, August 1, 2002) "Guiding Icarus [...] is timely and well written. I particularly enjoyed reading the chapters on Personalized Medicine and Stem Cells. People new to these "hot" topics will find [the] descriptions very informative." --Milo Gibaldi, Department of Pharmaceutics, University of Washington School of Pharmacy
"useful to biotechnologists, regulatory affairs managers, and corporate officers of biotech firms, as well as bioethicists..." (Genetic Engineering News, July 2002)
"...if you read The Economist you'll doubtless find this of interest..." (Focus, August 2002)
"...offers an insider's view on why a bridge is needed to merge bioethics with corporate needs...written for the general audience...is especially useful to biotechnologists, regulatory affairs managers, and corporate officers of biotech firms, as well as bioethicists..." (Genetic Engineering News, Vol. 22, No. 13, July 2002)
"...lays out a blueprint for executives...focusing on four subjects..." (HBS (Harvard Business School) Working Knowledge, July 2002)
"This book should stimulate much useful discussion in the biotechnology industry...the author should be congratulated." (Nature Biotechnology, August 1, 2002) "Guiding Icarus [...] is timely and well written. I particularly enjoyed reading the chapters on Personalized Medicine and Stem Cells. People new to these "hot" topics will find [the] descriptions very informative." --Milo Gibaldi, Department of Pharmaceutics, University of Washington School of Pharmacy
A Featured Book Recommendation with a link to buy the book on Harvard Business School's website: "...lays out a blueprint for executives...focusing on four subjects..." --HBS (Harvard Business School) Working Knowledge, July 2002
